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INTRODUCTION
Retinoids are known to play an important role in many biological processes, such as cell growth, differentiation, and development (l-3). One of the most striking effects of the retinol metabolite retinoic acid (RA) is its ability to induce differentiation in embryonal carcinoma (EC) cells. The murine P19 EC cell line, for example, 0666-6609/93/0604-0615$03 .00/0 Molearler Endocrinology Copyright 0 1993 by The Endcmne Society which shares many characteristics with the pluripotent inner cell mass cells of the early mouse embryo, is able to differentiate into a variety of cell types upon the administration of RA (4, 5). The biological action of RA is mediated by two specific sets of nuclear retinoid receptors, RA receptors (RARs) anti retinoid X-receptors (RXRs), which belong to the multigene family of steroid/thyroid hormone receptors (for reviews, see . These receptors function as ligand-inducible transacting transcription factors and modulate the expression of target genes by interaction with specific &-acting DNA elements, the hormone response elements. Both subfamilies of retinoid receptors consist of several receptor subtypes, referred to as RARa, and RXRCI, $3, . Recent studies have identified 9-ci.s RA as the natural ligand for RXRs (18, 19) .
The three RAR subtypes were found to be distinctly and spatio-temporally expressed during mouse embryogenesis (20-23) suggesting a specific role for each subtype in development. In addition, different isoforms of each RAR subtype have been identified, which differ in their N-terminal A region (13, (24) (25) (26) . The mRNAs of these isoforms are generated by differential promoter usage and alternative splicing. For RAR& for example, three mouse mRNA isoforms (mRARP1, $2, and -p3) have been found that are transcribed from two different promoters in the same gene (26). The most up-stream located promoter is used for the transcription of mRNAp1 and $3, which are predominantly expressed in fetal and adult brain and thought to play a role in the development of the central nervous system. RARPP mRNA, transcribed from the other promoter, is highly expressed in RA-treated EC and embryonic stem cells, which suggests that this isoform may be important during early stages of development (26) .
In murine EC cells, RARa and -y are constitutively expressed, whereas the RAR/3 gene is rapidly and strongly induced after RA treatment (27, 28) . This induction is due to transcriptional activation of the RARP2 promoter, which contains a RARE positioned five nu-ElA Coactivator of RA-Dependent RARflP Activation 605 cleotides in front of the TATA box (29, 30) . The expression of other genes, such as the laminin-Bl gene, is altered later during RA-induced differentiation of EC cells, generally some 24-48 h after RA addition (31). The promoter of the laminin-Bl gene was also found to contain a RARE, although different from the RARE identified in the RARPP promoter and with a lower affinity for RARs (32) . Interesting in this respect is the identification of the so-called coregulators, proteins that are able to associate with RARs and thereby modulate their affinities for different RAREs (33) . In fact, members of the RXR subfamily have been recently identified as coregulators of RAR action (17, (34) (35) (36) (37) (38) . Adenovirus El A products are required for transactivation of adenovirus early genes.
The role of ElA in cellular transformation has been well studied (for reviews, see Refs. 37 and 38) . ElA alone has the property of immortalizing primary cells in culture (39, 40) and in cooperation with the adenoviral El B gene or an activated ras gene is capable of fully transforming cells (40, 41) . The ElA transcription unit produces two major spliced mRNAs, the 12s and 13s forms, which encode proteins consisting of 243 and 289 amino acids, respectively. These proteins are able to activate or repress the transcription of both cellular and viral genes (37, (42) (43) (44) (45) . Three regions (CRl-3) have been identified in the ElA 13s protein, which are highly conserved among the El A proteins from different adenoviruses. The El A 12s protein contains CR-1 and CR-2, which are required for cellular transformation, but lack CR-3, which is known to be necessary for transcriptional activation of viral early genes (for reviews, see Refs. 38 and 46) . In general, the 13s ElA product is involved in the transactivation of target genes, while the 12s protein functions as a repressor.
The molecular mechanism underlying gene regulation by El A is still not completely understood. Studies to unravel this mechanism have been made complicated by the failure to show that ElA could bind to specific DNA sequences (47, 48) . However, analyses of the promoter regions of El A-inducible genes lead to the identification of a DNA element involved in mediating the effect of ElA on transcription. This element appeared to be identical to the CAMP response element (CRE) and binds the cellular transcription factor ATF or CRE-binding protein (CREB) (for review, see Ref. 38 and references therein). In addition, for several genes, TATA-binding factors were found to play an important role in mediating the transactivation by ElA (43, [49] [50] [51] . Apart from interactions with DNA-binding proteins, ElA was also shown to interact with other cellular proteins, among them the retinoblastoma gene product (52, 53) . These findings lead to the postulation that El A exerts its function through multiple cellular or viral proteins.
In EC cells, the existence of an El A-like activity has been reported which is lost upon differentiation with RA (54, 55). This was based on the observation that the adenoviral E2A gene, expression of which requires the El A proteins, is active in EC cells (42) whereas, on the other hand, the polyoma virus enhancer, which is repressed by ElA (44, 56) , also has reduced activity in undifferentiated cells, but becomes active upon differentiation (57-59). El A-like activity could also be detected in mouse oocytes and preimplantation-embryos (60, 61). However, the factors that form the basis of this El A-like activity have yet to be identified. In this report we studied RA-dependent RARP2 promoter activation in END-2 cells, a RA-differentiated derivative of P19 EC cells (62) and in END-2 ElA cells, which have been stably transfected with an El A expression vector (63). In contrast to the situation in END-2 cells, the RARP2 gene is strongly activated by RA in the El Aexpressing derivatives, indicating a possible involvement of El A in RA-induced RARB2 promoter activation. To test this hypothesis, we performed transient transfection assays in several cell lines using RAR/32 promoter-containing reporter constructs and El A expression vectors. We demonstrate that RA-dependent RARP2 promoter activation can be restored by cotransfection of ElA expression vectors in cells in which normally this activation is not observed. In addition, we show that two regions in the RARP2 promoter are involved in conferring the stimulatory effect of El A and RA. Finally, we postulate that the cellular equivalent of El A is able to function as a coregulator of RA-dependent RARP2 promoter activation.
RESULTS
RAR Expression in END-2 and END-2 ElA Cells P19 EC cells, which form a model system for studying early mouse embryogenesis, are tumorigenic cells and exhibit all of the characteristics of transformed cells, including anchorage-independent growth and proliferation in the absence of growth factors. END-2 cells, cloned from P19 EC cells differentiated by aggregation in the presence of RA, have lost the transformed phenotype and possess endoderm-like characteristics (62). From this cell line, three clones have been isolated that are stably transfected with the adenovirus type 5 El A gene, designated clones 20, 23, and 24. These clones, which express both ElA mRNA and protein, have regained some characteristics of EC cells and posses a more EC cell-like morphology (63).
We questioned whether the El A-induced change in differentiation state in END-2 cells is accompanied by an altered expression pattern of RARs. To address this, we cultured END-2 and END-P-ElA cells for 0, 8, or 24 h in the presence of RA and determined RAR expression by RNase protection analyses using RARa-, -p-, and -r-specific complementary riboprobes, as described in Materials and Methods. Since these probes are directed against the C/D and E/F regions, all isoforms present will be recognized. , and 24 h with RA was simultaniously hybridized with RAR~Y, -@-, and -y-and GAPDH (gap)-specific riboprobes in a RNase protection analysis. As controls, lanes indicated (Y, j3, and y show the protected mRNA fragments when the RARa, -8, and -y riboprobes were hybridized alone to RNA isolated from P19 EC cells treated for 24 h with RA. B, Relative RARB expression was determined by quantification of the RARp transcript levels shown in A and correction for the GAPDH transcript levels.
affected by RA treatment. RARP transcripts could not be detected in untreated END-2 and END-P-ElA cells; however, RA treatment resulted in the induction of RAR/3 expression. Interestingly, this induction appeared to be stronger in the El A-expressing cell lines than in the parental END-2 cells (see also Fig. 1 B) .
RA-Dependent RAR82 Promoter Activation in END-2 and END-2 ElA Cells
The strong RA-dependent increase in the amount of RARP transcripts in END-2 El A cells, which was observed to a lesser extent in the parental cell line END-2, suggested the possibility that stable expression of ElA affects this induction. We next investigated whether this was due to an enhanced transcriptional activation of the RAR/32 promoter in END9-ElA cells compared to the situation found in the parental END-2 cell line. We, therefore, performed transient transfection assays with a chloramphenicol acetyltransferase (CAT) reporter construct containing the -1470/l 56 fragment of the human RARP2 promoter and determined CAT activity in untreated and RA-treated END-2 and END-2-El A cells. Figure 2 shows a strong RA-dependent increase in CAT activity on this construct in the ElAexpressing clones 20 and 23 and, to a lesser extent, in clone 24, while a much smaller induction is seen in END-2 cells. These results demonstrate that the enhanced level of RA-induced RARP expression in the El A-expressing END-2 cells compared with the nontransfected END-2 cells is due to a stronger activation of the RARPP promoter by RA.
The finding that the accumulation of RARB transcripts after RA treatment in the END-P-ElA cell lines (Fig. 1) is not completely consistent with the observed increases in CAT activity might be explained by differences in transcript and/or protein stability in these cells. In addition, the variation found in the level of activation among the three END9-derived clones could be due to different levels of El A proteins expressed in each cell line (63).
Effects of ElA 12s and 13s on RA-Dependent RARB2 Promoter Activation in Different Cell Types As mentioned previously, stable expression of El A in END-2 cells causes a change in their state of differentiation (63). Therefore, the enhanced RA-dependent RARP2 promoter activation observed in END9-El A cells could be due to an indirect effect of El A. To investigate whether El A affects the RARBP promoter more directly and to examine which ElA protein, the 12s or the 13s form, enhances the level of RA-induced RAR@P transcription, we transfected END-2 cells with the -1470/156 CAT construct in combination with 1 pg DNA ElA expression vectors and performed CAT assays in the absence and presence of RA. Interestingly, after RA treatment, cotransfection of the vector pE1 A 13s resulted in an increase in CAT activity, while a small repressive effect was observed when using the pE1 A 12s vector (Fig. 3 ). In the absence of RA, cotransfection of the El A expression vectors had no effect on the level of CAT activity (not shown). One microgram of ElA expression vector was used in these assays because this amount appeared to give the optimal response in dose-response studies (not shown). A vector containing a P-actin promoter-driven CAT gene served as a positive control in the assay.
In addition, we studied the effects of both EIA products on RA-dependent RARP2 promoter activation in two other cell lines: the human colon tumor cell line HCTI 16, in which RARP2 activation cannot normally be detected (van der Leede, B-j. M., in preparation), and PI9 EC cells, which show strong RA-dependent RARP2 promoter activation. Therefore, the CAT assays performed in END-2 cells were repeated in these cell lines. As shown in Fig. 3 , in the absence of ElA expression vector, the RARP2 promoter is insensitive to the inducing effect of RA in HCTI 16 cells. However, cotransfection of pE1 A 13s enables the promoter to be activated by RA, whereas cotransfection of the pElA 12s vector has no effect.
In P19 EC cells, the EIA 12s product has a repressive effect on RA-induced CAT activity, while the 13s product leads to even stronger activation of the RARP2 promoter by RA (Fig. 3) .
From these results it can be concluded that dependent on the cell lines used, 12s El A has no or a repressive effect on RA-dependent RARP2 promoter activa-607 tion, while 13s EIA can stimulate and in other cases can restore this activation.
Determination of ElA-Sensitive Regions in the RARB2 Promoter
We next examined which sequences of the RARP2 promoter are involved in conferring the stimulatoty or repressive effect of El A in transient transfection assays in the different cell lines.
First, END-2-cl23 cells were transfected with several CAT reporter constructs containing 5'-progressive deletions of the -1470/l 56 RARP2 promoter fragment (Fig. 4A) , and their activation by RA was determined. Figure 48 shows that constructs containing the sequences between -180 and 156 have comparable levels of activation, while a 3-to 4-fold decrease in CAT activity is observed when the RARP2 promoter fragment encompassing nucleotides -180 to -63 is removed. In addition, the RARE-containing -63/l 56 fragment is sufficient for mediating RA-dependent activation. Secondly, we transfected these deletion constructs in combination with the pE1 A 13s or pE1 A 12s vector in HCTI 16 cells (Fig. 4C ). As described above for HCTI 16 cells, 12s El A had hardly any effect on RARP2 promoter activation. Using pE1 A 13S, the levels of induction as measured on the -180/l 56 construct appeared to be similar to the levels found when the -1470/l 56 reporter was used. However, a 3-fold lower level of RA-induced CAT activity was observed on the -63/l 56 construct. As controls, expression of the 12s and 13s products in HCTI 16 cells in the absence of RA resulted in only a slight increase in the basal level of transcription in the case of 13s El A.
Finally, in P19 EC cells, the -180/156 and -63/156 CAT constructs were tested for activation by RA, while the amount of cotransfected pE1 A 12s and pE1 A 13s expression vector was varied. Figure 4D shows that the El A 13s product is able to enhance expression of the already strongly activated RARP2 promoter by 50-70% when 1.25 or 2.5 pg pE1 A 13s was cotransfected with the -180/156 reporter construct. Transfection of higher amounts of pE1 A 13s did not lead to higher levels of induction (not shown). In contrast, cotransfection of the pE1 A 12s expression vector with the same reporter construct resulted in an approximately 50% reduction in RA-induced RARP2 promoter activation compared to the normal level of induction. Interestingly, when using the -631156 reporter construct, the EIA 13s product had a repressive effect on activation of the promoter by RA, which was of the same order as the repression found with the El A 12s product on this reporter (Fig. 40) . Taken together, the deletion studies in the El A stably transfected END-2cl23 cell line and the cotransfection experiments in HCTl16 and P19 EC cells show that two regions in the RARB2 promoter mediate the effects of El A and RA: the RARE containing -63/156 promoter fragment and sequences located between -180 . IllL -1.V. -,a. -1,.
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-.a/ *la. In earlier studies in P19 EC cells, we found that besides the RARE, more up-stream located sequences are involved in both mouse and human RARP2 promoter activation by RA (28, 64) . Moreover, we have recently identified an element, located at position -99 to -92 in the RARPP promoter, that enhances RA-dependent promoter activation (65). This element, designated CRE-82, is conserved in both the human and mouse RARB2 promoter and consists of the motif TGATGTCA, which closely resembles the CRE consensus TGACGTCA. We demonstrated that CRE-/I2 can bind members of the ATF/CREB transcription family (for review, see Ref. 66) by competition experiments in gel retardation assays using consensus CRE-containing oligonucleotides (65). A specific member, ATF-2, has been reported to mediate transcription activation by ElA (67). Besides CRE-P2, a second putative regulatory element was localized on position -84 to -78 with homology to the TPA response element (TRE) or APlbinding site (68, 69). However, we could not find a role for this element, designated TRE-P2, in RA-dependent RARPP promoter activation in P19 EC cells.
To examine whether these elements are involved in mediating the stimulatory effect of ElA on the -180/ -63 RARP2 promoter fragment, HCT116 cells were transfected with the -180/156 reporter construct in which either CRE+32 (ACRE) or TRE-@2 (ATRE) was mutated, and CAT activity was determined in the absence or presence of El A expression vectors and RA. As observed earlier, no significant increases in CAT activity could be detected after RA treatment and/or cotransfection with pE1A 12s on any of the reporter constructs used (Fig. 5) . Interestingly, upon cotransfection with pE1A 13S, similar levels of RA-induced CAT activity were found on the -63/l 56 and ACRE reporter constructs, while the wild-type -180/l 56 construct mediated a 3-fold higher level of CAT activity. Mutation of TRE-/I2 did not affect the responses of the -180/ 156 promoter fragment to El A 13s and RA. These results demonstrate that CRE-/32 mediates the stimulatory effect of El A 13s on the -180/-63 region upon RA-dependent RARP2 promoter activation.
ElA Enhances Protein Binding to the -180/-83 RAW32 Promoter Region
We next questioned whether there are differences in nuclear protein binding to the -180/-63 RAR@2 promoter region in P19 EC, END-2, and END-2-cl20 cells. To assess this, we performed gel retardation assays with 32P-labeled -1 SO/-63 promoter fragment and nuclear extracts from these cells cultured in the presence or absence of RA. As shown in Fig. 6 , predominantly two protein-DNA complexes, named 1 and 3, were found in nuclear extracts from untreated P19 EC cells. In extracts from P19 EC cells treated for 24 h with RA, an additional protein-DNA complex, called 2, could be clearly detected. In addition, upon longer periods of film exposure to the polyacrylamide gel used for the gel retardation assay, it appeared that a low amount of complex 2 is present in extracts from untreated P19 EC cells (results not shown). Binding complexes 1 and 3 were found in END-2 cell nuclear extracts, while complex 2 could not be detected in either untreated or RA-treated cells. The apparent increase in the amount of complexes 1 and 3 formed after RA treatment, as shown in Fig. 6 , is due to a lower protein content of the extracts derived from untreated END-2 cells used in this experiment and is normally not observed. All three complexes were found in nuclear extracts from untreated and RA-treated END-2-1~120 cells, and protein binding to the -180/-63 promoter region using these extracts appeared to be stronger than that in the extracts derived from P19 EC and END-2 cells, which normally show similar levels of complex l-and 3-binding activities.
Competition experiments using nuclear extracts from RA-treated END-2cl20 cells showed the specificity of the three binding complexes; binding activity was almost completely lost when using an excess of cold probe, and nonspecific competition with a RARE-02 containing oligonucleotide did not reduce binding. Interestingly, CRE$2-containing oligonucleotides specifically competed for complex e-binding activity when using nuclear extracts from END-2cl20 and P19 EC cells (Fig. 7 and data not shown) . TRE-82 oligonucleotides did not compete for any of the complexes (not shown). These findings suggest that there are additional, yet unidentified, protein-binding sites localized on the -180/-63 RARP2 promoter fragment.
Taken together, these results show that stable expression of ElA in END-2 cells increases the binding of complex 1-and 3-binding activities to the -180/-63 RARpP promoter region and, moreover, induces protein binding to CRE-@2. Furthermore, RA treatment of P19 EC cells enhances CRE-P2 binding, which was not observed in END-2-and END-2-cl20 cells.
Correlation between RA-Dependent RAR82 Promoter Activation and the Presence of Cellular ElA
The results presented above show that El A can act as a coactivator of RA-dependent RARB2 promoter activation. Since EC cells are thought to contain a cellular equivalent of El A which is lost upon differentiation, we postulate that the strong activation of the RARP2 promoter by RA in P19 EC cells could be facilitated by this endogenous ElA-like factor. In addition, the weak response or even the insensitivity of the promoter to RA in differentiated (END-2 and HCT116) cells could then be explained by assuming that these cells contain only low amounts of this factor or are devoid of it. To determine whether there is a correlation between RA-dependent PIAFt/ promoter activation and the presence of an endogenous El A-substituting activity, we monitored El A-like activity in the P19 EC, END-2, and HCT116 cell lines. Therefore, these cells were transfected with a CAT reporter construct containing the El A-dependent E2A promoter, the activity of which reflects the presence of El A-like activity, as has been demonstrated recently (70). Interestingly, in P19 EC cells, the E2A promoter appeared to be as active as in the El A-expressing human fetal kidney cell line 293
ElA Coactivator of RA-Dependent RAR@2 Activation 611 (71) (Fig. 7) . In this cell line, the RARP2 promoter can also be strongly activated by RA (not shown). In END-2-ElAcl23 cells, strong E2A promoter activity was observed, while much lower levels of activity were detected in the END-2 and HCT116 cell lines (7% and 5%, respectively, of that in 293 cells). Cotransfection of the expression vector pE1 A 13s resulted in an increase in E2A promoter activity, most profoundly in the END-2 and HCTl16 cell lines, and to a lesser extent in the El A-expressing cell lines and P19 EC cells. These data indicate the presence of a high level of El A-like activity in P19 EC cells and much lower levels in END-2 and HCT116 cells, supporting our hypothesis that this factor functions as a coactivator of RA-dependent RARBP promoter activation.
DISCUSSION
RA-induced differentiation of P19 embryonal carcinoma cells is accompanied by strong transactivation of the RARP2 promoter by ligand-activated RARs, mediated by a RARE located in the proximity of the TATA box. We examined RA-dependent RARP2 promoter activation in the RAdifferentiated P19 EC-derived END-2 cell line (62) and in their El A-transfected clonal derivatives (63) and found strong activation in the El A-containing cells that was not observed in the parental cell line (Figs. 1 and 2 ). This result prompted us to investigate whether ElA can function as a coactivator of RAdependent RAR/32 promoter activation. A comparative analysis of promoter activation in END-P, HCT116, and P19 EC cells by transient transfection assays using El A expression vectors showed that the El A 13s product enhances or restores RARP2 promoter activation in these cell lines, while the El A 12s product either has no or a repressive effect (Fig. 3) . In both END-B El A stable transfectants and cotransfection experiments in P19 EC and HCT116 cells, deletion analysis of the RARj32 promoter revealed the presence of two El A-responsive regions; a 117-basepair (bp) fragment between -180 and -63 and a fragment that contains the RARE and the TATA element (Fig. 4) . In addition, a CRE-related sequence at position -99 to -92 in the 117-bp fragment was identified as an El A response element (Fig. 5) . Protein binding studies to the -180/ -63 promoter region in gel retardation experiments with nuclear extracts from different cell lines showed that CRE-PBbinding activity is enhanced after RA treatment in P19 EC cells, which was not the case in END-2 and END-BE1 A cells, and that El A increases protein binding to the -180/-63 fragment (Fig. 6) . Furthermore, examination of endogenous El A-like activity in P19 EC, END-P, and HCT116 cells by determining the activity of an E2A-promoter/CAT construct (Fig. 7) suggested a correlation between the presence of an ElAlike activity and the response of the RARP2 promoter to RA.
Evidence for the Involvement of a Cellular ElA-Like Factor in RAW32 Promoter Activation
The reported activation of the RARPP promoter by RA in, for example, CV-1 and COS-1 cells requires additional expression of RARs and is weak compared to the level of activation found in P19 EC cells (72, 73) . This indicates that in P19 EC cells, the conditions are optimal for RA-dependent promoter activation. The demonstrated high level of RXRB expression in P19 EC cells, which has been found to function as a coregulator of RAR-dependent promoter activation and increases transcriptional activation by high affinity binding of RAR-RXR heterodimers to RAREs (34) could partially explain the strong RARP2 promoter activation in these cells. In addition, the results presented here suggest a role for the cellular equivalent of El A in activation of the RARP2 promoter in these cells, which could function as a coactivator in a similar way as El A. Moreover, the weak or even absent promoter response to RA in differentiated cells could then be explained by the loss of El A-like activity upon differentiation. The evidence for this hypothesis is as follows. 1) The examination of the presence of an El A-like activity in P19 EC, END-P, and HCT116 cells revealed a correlation between the presence of El A-like activity and RAdependent RARP2 promoter activation. In a recent report it was shown that the hepatoma cell line HepG2 contains a relatively high level of El A-like activity (74). This finding supports our hypothesis, since the RARB2 promoter has been shown to be relatively strongly activated by RA in these cells (11). 2) In END-2 and HCT116 cells, ElA is able to stimulate or even restore promoter activation by RA (Figs. 3 and 4) . This suggests that ElA can substitute for the endogenous factor present in EC cells. 3) In P19 EC ceils, cotransfection of small amounts of ElA expression vector had a repressive effect on RA-dependent activation, as determined on the -63/156 RAR/32 promoter/CAT construct (Fig. 4) . This can be explained by assuming that P19 EC cells contain an optimal amount of an El A-like factor, and by additional expression of El A, other participating factors are titrated out and become rate limiting. Candidates for such participating factors are RARs, RXRs, and TATAbinding factors. Interestingly, when the El A-sensitive CRE-containing -180/-63 promoter region was included in the reporter construct, the ElA 13s product could enhance activation of the promoter by approximately 50% (Fig. 4) . This indicates that the ElA interaction sites of the protein that binds to this promoter region, probably ATF-2, are not saturated by the endogenous El A-like factor.
Taken together, our results suggest an important role for the cellular equivalent of El A in the regulation of RARB2 promoter activation. Since El A-like activity has also been detected in mouse preimplantation embryos (60) it is possible that this activity contributes in vivo to the spatio-temporal expression of RARP2.
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Possible Mechanism for ElA-Mediated RAW32 Transactivation
We have shown here in both stably transfected cell lines and cotransfection experiments that the -63/l 56 promoter region alone, which contains the RARE and the TATA element and no other known functional elements, was sufficient to mediate the stimulatoty effect of El A on RA-dependent RAR82 promoter activation (Figs. 4 and 5) . Recently, Schijler et al. (75) reported that Ott-4 and El A are sufficient for distance-independent activation of the basal transcription machinery. They propose a model in which El A or its cellular equivalent serves as a bridging factor between Ott-4 and the transcription initiation complex. Our results could be explained in a similar way by assuming that El A is able to interact with both TATA-binding factors and ligandactivated RARs, thereby facilitating activation of the promoter. Since the RARE is closely positioned to the TATA element, it would be interesting to investigate whether this interaction is distance independent in analogy to the situation found with Ott-4 and ElA (75). In addition, the TATA-binding factor TFIID has recently been reported to be able to interact directly with ElA (76, 77). Whether such interactions are also possible with RARs remains to be proven.
The involvement of a CRE-related sequence located in the -180/-63 region in the enhancement of RARP2 promoter activation suggests the participation of members of the ATF/CREB transcription factor family (for review, see Ref. 66) in promoter activation by RA and El A. A specific member of this family, ATF-2, has been shown to be able to interact with El A directly (67). It is thought that the interaction of ElA with promoterbound ATF-2 results in transcriptional activation by the positioning of the El A-activating region at the promoter (67). Such a mechanism could also account for the observed stimulatory effect of ElA found on CRE-P2. In addition, more evidence for the involvement of ATF-2 in RA-and El A-dependent RARP2 promoter activation is provided by the fact that CR-3, which is absent in the El A 12s product, is involved in the interaction with ATF-2 (67), which correlates with and also provides an explanation for our observation that El A 13s and not 12s enhances promoter activation via CRE-/32 (Fig.  5) .
Besides a possible direct interaction between ElA and the CRE-Be-binding activity, our results show that stable expression of El A in END-2 cells increases protein binding to the -180/-63 RARPP promoter region and particularly induces CRE-Be-binding activity (Fig. 6) . However, since in earlier studies we found that the increase in CRE-@P-binding activity induced by RA in P19 EC cells (see also Fig. 6 ) did not correspondingly result in an enhancement of CRE-@P-mediated transcription (65), it is too early to conclude that ElA enhances RARP2 promoter activation in a more indirect fashion by increasing CRE-BP-binding protein levels. Additional studies will be necessary to elucidate more precisely the manner in which El A enhances or restores RA-dependent RARP2 promoter activation.
We propose a model for the way in which El A affects RA-dependent RARPP promoter activation, which combines the two mechanisms postulated for El A-mediated transactivation earlier mentioned; El A affects RARPP promoter activation by functioning as a bridging factor between RARs or attached coregulators (RXRs) and the basal transcription machinery and enhances promoter activity further by interaction with ATF-2.
MATERIALS AND METHODS

Cells and Plasmids
The cells (END-2, END-2 ElA, P19 EC, HCT116, and 293) used in the experiments were cultured on gelatin-coated dishes in a 1:1 mixture of Dulbecco's Modified Eagle's Medium and Ham's F-l 2 containing 7.5% fetal calf serum.
A number of the CAT constructs used in transient transfection assays have been described previously (28). CAT constructs encomoassina nucleotides -335 to 156. -180 to 156. and -63 to 156 of tLe human RAR(32 promotk were gener: ated by subsequently subcloning a Ddel-BarnHI, a /-/pallBarnHI, and a Smal-BamHI promoter fragment in the promoterless pKTCAT vector.
The -180/156 CAT construct containing either a mutated CRE-or TRE-related sequence was generated by site-directed mutagenesis using the Altered Sites In Vitro Mutagenesis System Kit (Promega, Madison, WI). Briefly, single-stranded DNA derived from the vector pSELECT inserted with the /-/pallBamHl promoter fragment functioned as a template for mutagenesis using the synthetic oligodeoxynucleotides 5'-ATCCTGGGAGTTGGaGATGTtAGACTAGTTGGGTC3'or 5'-ATGTCAGACTAGTgtGGTCAlTTGAAGG-3' encompassing nucleotides -112 to -79 or -97 to -70 of the human RARPP promoter, respectively, and with the altered bases shown in lowercase letters. In a consensus CRE or TRE, these alterations have been shown to abolish the function of these elements (68, 76) .
The adenovirus E2A promoter-containing CAT construct, pSCAT, and the ElA (Ad2) expression vectors pEIASV, pElA 12s. and pElA 13s. have been previously described (79, 80) .
Plasmids used for the generation of 32P-labeled riboprobes contained murine RARa-, -p-, and -r-specific cDNA subfragments (a 129-bp Sstl-Pstl fragment, a 116-bp EcoRI-Pstl fragment, and a 202-bp Ddel-Apal fragment, respectively) and a 58-bp Haelll fragment obtained from murine glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA subcloned in the pBluescript vector SK-(Stratagene, La Jolla, CA) (81).
RNA Isolation and RNase Protection Analyses
Total cellular RNA was isolated using the acid-phenol single step method (82).
Complementary 32P-labeled riboprobes directed against part of the C and D regions (RARa), the F region (RAR@), and part of the E and total F regions (RARr) were transcribed using T3 or T7 RNA polymerases. Probes (1 O"-1 O5 cpm) were simultaneously hybridized to total RNA (15 pg) overnight at 45 C in a buffer containing 80% (vol/vol) formamide, 40 mM piperazine-N,N'-bis-(2ethanesulfonic acid) (pH 6.4), 0.4 M NaCI, and 1 mM EDTA. Subsequently, samples were digested with RNase Tl for 30 min at 37 C, treated with 0.1 mg/ml proteinase-K and 0.5% sodium dodecyl sulfate, and extracted with phenol. After ethanol precipitation, the samples were run on a 6% polyacrylamide sequencing gel. The fixed gel was exposed at -80 C for 3 days to x-ray film using an intensifying screen. A ElA Coactivator of RA-Dependent RARpP Activation 613 GAPDH complementary riboprobe was always included in the assay to correct for possible differences in the amount of RNA loaded in each lane (83). Transcript levels were quantified by using a Molecular Dynamics Phospho lmager with Image Quant software.
Transient Transfection Assays END-P, END-2 ElA, P19 EC, HCT116, and 293 cells cultured on gelatin-coated dishes (diameter, 3.5 cm) were transfected by calcium phosphate coprecipitation (84) using 10 pg CAT reporter plasmid DNA and varying amounts of El A expression vectors in combination with 1 pg SVP-LacZ as an internal control. After 16 h, fresh medium was added to the cells together with RA (final concentration, 1 Oe6 M) when appropriate. Cells were harvested 24 h later and assayed for CAT activity, as previously described (85). The reaction products separated by TLC were quantified by using a Molecular Dynamics Phospho lmager (Eugene, OR) with Image Quant software. After normalizing transfection efficiency with the LacZ activity, CAT activity is expressed as the percentage conversion of the total amount of ['4C]chloramphenicol into its acetylated products. When using the p2CAT reporter plasmid, CAT activity is depicted as the percentage of that of the control, &actin/CAT, expression of which is not modulated during differentiation. Routinely, transfection experiments were repeated at least three times.
Gel Retardation Assays
Nuclear protein extracts were prepared by the miniscale method, as described by Lee et al. (86) . Protein concentrations were determined by the Bio-Rad protein assay according to the manufacturer's protocol.
The sequences of the double stranded oligonucleotides used in the assay were: CRE-B2, TGAGTTGGTGATGTCA-GACTAG; and RARE-BP, CCGGGTAGGGTTCACCGAA-AGT-TCACTCG.
The -180/-63 RAR/32 promoter fragment used as a probe was generated by labeling the cohesive ends with [@PI deoxy-ATP using the Klenow fragment of DNA polymerase-I, followed by gel filtration using Sephadex G-50 spin columns (Pharmacia, Piscataway, NJ).
The electrophoretic mobility shift assay used is based on the procedures described by Fried and Crothers (87) with slight modifications. Nuclear extracts (4 pg) were incubated in a reaction buffer (20 ~1) containing 16 rni Tris-HCI (pH 8.0) 0.1 mM EDTA. 75 mM KCI, 10% (vol/vol) olvcerol, 1 mM dithiothreitol, O:l mg/ml poly-(dldC),' 106 ng/mi pUCl8 plasmid DNA, and 0.1 ng 32P-labeled DNA fragment (SA, 1 x lOa/ pg) at room temperture for 20 min. An equal volume of loading buffer, containing 20% (vol/vol) Ficol, was added, and the mixture was immediately ioaded onto a 4% polyacrylamide gel and electrobhoresed in 0.5 x TBE (25 mM Tris. 25 mM boric acid, and 1 'mrv EDTA) for 4 h. The gel was fixed in 10% (vol/ vol) methanol-l 0% (vol/vol) acetic acid, dried, and exposed to Kodak XAR film for 2 days. Kastner P, Krust A, Mendelsohn C, Gamier J-M, Zelent A. Leroy P, Staub A, Chambon P 1990 Murine isoforms of retinoic acid receptor y with specific patterns of expression. Proc Natl Acad Sci USA 87:2700-2704 Leroy P, Krust A, Zelent A, Mendelsohn C, Garnier J-M, Kastner P, Dierich A, Chambon P 1991 Multiple isoforms of the mouse retinoic acid receptor (Y are generated by alternative splicing and differential induction by retinoic acid. EMBO J 10:59-69 Zelent A, Mendelsohn C, Kastner P, Krust A, Garnier J-M, Ruffenbach F, Leroy P, Chambon P 1991 Differentially expressed isoforms of the mouse retinoic acid receptor fi are generated by usage of two promoters and alternative splicing. EMBO 
